RegulatoryCompany release

Cumberland to file NDA for ifetroban in Duchenne cardiomyopathy under FDA rolling review

🇺🇸 Cumberland Pharmaceuticals Inc (CPIX) · Tue 10 Nov 2026

Cumberland Pharmaceuticals plans an FDA submission after a pre-NDA meeting, and also reported Phase 2a systemic sclerosis data and Q3 net income lifted by the Apotex transaction.

Cumberland Pharmaceuticals said on 10 November 2026 that it will submit a New Drug Application to the US Food and Drug Administration for ifetroban as a treatment for cardiomyopathy in Duchenne muscular dystrophy. The company said the filing follows a pre-NDA meeting with the agency.

The FDA has also granted a rolling review for the application. As general context, rolling review allows a sponsor to submit completed sections of an application in stages rather than waiting to deliver the whole dossier at once. The source material provided does not set out a submission timetable.

In a separate update, Cumberland reported top-line results from its Phase 2a ASSIST-SSc study of ifetroban in systemic sclerosis. The company said no serious adverse events were related to the treatment. Efficacy details were not included in the information available for this article.

On the financial side, the company posted third-quarter net income of $77.8 million. It attributed the result to the gain from its $100 million transaction with Apotex, which closed on 1 July.

What it means for your team

  • Regulatory teams tracking rare paediatric and neuromuscular indications should note that a pre-NDA meeting and rolling review are in place for ifetroban in Duchenne cardiomyopathy.
  • Pharmacovigilance teams may wish to follow the safety profile of ifetroban as more data emerge; the Phase 2a systemic sclerosis study reported no related serious adverse events.
  • Market-access and business-development teams can note that the Apotex deal, worth $100 million and closed on 1 July, drove Cumberland's Q3 profit.

Company's press release (SEC filing): Cumberland Pharmaceuticals Inc ↗

Article written by VigiEye from the official source (Cumberland Pharmaceuticals Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →